Silexion Therapeutics (SLXN) selects CRO for SIL 204 Phase 2/3 work

Rhea-AI Filing Summary

Silexion Therapeutics Corp filed a current report to share news from a recent press release. The company announced that it has selected a contract research organization to support its upcoming Phase 2/3 clinical trials for its candidate SIL 204, marking a step toward more advanced clinical development.

The press release, dated September 4, 2025, is included as Exhibit 99.1 and is furnished under Item 7.01, meaning it is provided for informational purposes and is not deemed filed under the Exchange Act or incorporated by reference into Securities Act filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000202241600-0000000972NASDAQNASDAQ00020224162025-09-042025-09-040002022416slxn:OrdinarySharesParValue00135PerShareMember2025-09-042025-09-040002022416slxn:WarrantsExercisableForOrdinarySharesAtAnExercisePriceOf155250PerShareMember2025-09-042025-09-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 4, 2025

Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

Cayman Islands		001-42253		N/A
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

12 Abba Hillel Road Ramat-Gan, Israel		5250606
(Address of principal executive offices)		(Zip Code)

+972-3-7564999

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value $0.0135 per share		SLXN		The Nasdaq Stock Market LLC
Warrants exercisable for Ordinary Shares at an exercise price of $1,552.50 per share		SLXNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 4, 2025, Silexion Therapeutics Corp issued a press release entitled “Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL 204.” A copy of the press release is furnished with this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information in Item 7.01 of this Form 8-K, including the information in the press release furnished pursuant to this Item 7.01 of Form 8-K, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Form 8-K, including the information in the press release, shall not be deemed to be incorporated by reference in the filings of the registrant under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1	Press Release dated September 4, 2025
104	Cover Page Interactive Data File (formatted in Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SILEXION THERAPEUTICS CORP
Date: September 4, 2025	By: /s/ Ilan Hadar
	Name:	Ilan Hadar
	Title:	Chief Executive Officer

FAQ

What did Silexion Therapeutics Corp (SLXN) disclose in this 8-K?

Silexion Therapeutics Corp disclosed that it issued a press release announcing the selection of a contract research organization to support upcoming Phase 2/3 clinical trials for SIL 204.

What is SIL 204 in Silexion Therapeutics Corp's pipeline?

SIL 204 is a product candidate of Silexion Therapeutics Corp that is planned to enter Phase 2/3 clinical trials, for which a contract research organization has been selected.

How is the press release about SIL 204 referenced in the 8-K for SLXN?

The press release titled “Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL 204” is attached as Exhibit 99.1 and incorporated by reference in the 8-K.

Is the SIL 204 press release considered filed for liability purposes?

No. The information in Item 7.01, including the SIL 204 press release, is furnished, not filed, and is not subject to Section 18 liabilities of the Exchange Act or automatically incorporated into Securities Act filings.

When did Silexion Therapeutics issue the SIL 204 CRO press release?

Silexion Therapeutics issued the press release, included as Exhibit 99.1, on September 4, 2025.

Which exhibits are included with this Silexion Therapeutics 8-K?

The 8-K includes Exhibit 99.1, the press release dated September 4, 2025, and Exhibit 104, the cover page interactive data file formatted in Inline XBRL.